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Abstract
Hereditary diffuse gastric cancer (HDGC) is an inherited 
form of gastric cancer that carries a poor prognosis. 
Most HDGCs are caused by an autosomal dominant 
genetic mutation in the CDH1  gene, which carries 
a 70%-80% lifetime risk of gastric cancer. Given its 
submucosal origin, endoscopic surveillance is an unreliable 
means of early detection, and prophylactic gastrectomy 
is recommended for CDH1  positive individuals older 
than age 20 years. We describe the case of a male with 
recurrent gastric cancer who was diagnosed with HDGC 
secondary to the CDH1 mutation, and we also describe 
the patient’s pedigree and outcomes of recommended 
genetic testing.
Key words: Hereditary diffuse gastric cancer; Genetic 
testing; Genetic diseases; Gastric cancer; Lobular 
breast cancer; Inheritable diseases
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Individuals who carry the CDH1 gene mutation 
are at very high risk of acquiring hereditary diffuse 
gastric cancer, a cancer with a high mortality if not 
detected early. The clinical findings we describe in this 
case may aid medical practitioners in the assessment 
and testing of patients with a family history of gastric 
cancer and raise awareness about the importance of 
genetic testing for this condition.
Haley M Zylberberg, Keith Sultan, Steven Rubin
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INTRODUCTION
Gastric cancer is the fifth most common cancer and the 
third leading cause of cancer related death worldwide[1]. 
While most gastric cancers occur from sporadic 
mutations, inherited gastric cancers make up 1%-3% of 
cases and are referred to as Hereditary Diffuse Gastric 
Cancers (HDGC)[2]. The majority of HDGCs are caused 
by an autosomal dominant inheritance of an abnormal 
copy of the tumor suppressor gene CDH1. As the 
CDH1 gene has a high penetrance, mutations produce 
a multi-generational cancer syndrome that affects 
multiple organs[2]. The CDH1 gene mutation causes a 
70%-80% life time risk of gastric cancer in both men 
and women and a 40%-60% life time risk of lobular 
breast cancer[2,3]. Unfortunately, detection based on 
gastrointestinal symptoms and endoscopic surveillance 
has a poor prognosis. Therefore, the International 
Gastric Cancer Linkage Consortium (IGCLC) recom-
mends prophylactic gastrectomy in individuals with 
the CDH1 gene mutation between ages 20 to 30[2]. 
It is therefore imperative that patients with a family 
history of gastric cancer have a comprehensive family 
pedigree reviewed and undergo genetic testing for the 
presence of HDGC if they fit the criteria proposed by 
the IGCLC.
In this report, we describe the case of a Caucasian 
male who was found to have the CDH1 gene mutation 
and diagnosed with HDGC. We also describe the results 
of his family members’ genetic testing. 
CASE REPORT
At age 49, the patient presented with abdominal 
fullness and was found to have gastric signet ring adeno-
carcinoma, and was treated with a partial gastrectomy 
(Billroth Ⅱ). The patient had no evidence of metastatic 
disease at this time as evidenced by normal CT scans. 
The patient subsequently underwent triennial esophago-
gastroduodenoscopies (EGD) for surveillance of cancer 
recurrence. In 2012, at the age of 58, a surveillance 
EGD was performed with random biopsies taken from 
normal appearing mucosa in the gastric cardia, fundus, 
distal body, and anastomosis site. Only the biopsy from 
the distal gastric body revealed adenocarcinoma with 
signet cells; all other biopsy specimens were negative 
for cancer related pathology. Endoscopic ultrasound 
was performed and did not reveal any submucosal 
or mucosal aberrations. PET/CT showed no areas of 
increased activity suggestive of metastatic disease.  
Family history revealed that the patient’s mother 
was diagnosed with gastric cancer at age 59, when the 
patient was 17, and subsequently died from metastatic 
disease (Figure 1). The patient’s identical twin sisters 
were both diagnosed with gastric cancer at age 38, and 
died shortly thereafter. 
The patient underwent total gastrectomy, with 
lymph node sampling. The pathologic specimen showed 
a 0.6-cm tumor in the lesser curvature of the stomach 
with invasion into the lamina propria. Histologic analysis 
showed a poorly differentiated signet ring cell carcinoma 
(Figure 2), grade 3. Immunohistochemical stains for 
mucicarmine and keratin AE1/AE3 highlighted the 
signet ring cell carcinoma. No additional staining was 
performed. All 16 sampled lymph nodes were negative 
for pathology, and staging was deemed T1a.
The patient underwent a gene panel for known 
mutations linked to gastrointestinal cancers. The DNA 
sampled was from the patient’s lymphocytes and next-
generation sequencing was used. The patient tested 
positive for the CDH1 gene with aberration in the c.521 
dvpA and the STKII gene had a mutation of unknown 
significance with aberration in p.5354L. Testing for 
lynch syndrome and familial adenomatous polyposis 
syndrome were negative. Given the defined mutation, 
and with the patient’s encouragement, many of the 
patient’s family members underwent genetic testing. 
The patient’s pedigree is shown in Figure 1. In total, 
21 of the patient’s relatives underwent genetic testing, of 
which 12 were found to have the CDH1 gene mutation, 
including two of the patient’s sons. Of these 12 relatives, 
8 underwent prophylactic gastrectomy, despite having 
no concerning gastrointestinal symptoms. At the time 
of gastrectomy all 8 family members had evidence 
of gastric cancer when pathological specimens were 
histologically analyzed.  
DISCUSSION
HDGC, unlike the sporadic forms of gastric cancer, is 
composed of signet ring cells and originates diffusely 
throughout the gastric submucosa[4-6]. The sporadic 
form of gastric cancer is usually associated with 
Helicobacter pylori infection, which can lead to gastric 
atrophy and intestinal metaplasia[4,5,7,8]. Often with 
Helicobacter pylori associated gastric cancer, cells are 
arranged in a gland-like formation and begin in the 
mucosa[4,5,7,8]. As occurred in this case, the cancer found 
in HDGC related cases is usually poorly differentiated, 
which is a direct result of the CDH1 gene mutation. 
The CDH1 gene, located on chromosome 16, codes 
for E-cadherin, a calcium dependent cellular adhesion 
protein that is instrumental in maintaining epithelial cell 
structural integrity[2,5,6].  When this gene is mutated, 
the decreased E-cadherin expression promotes atypical 
cellular architecture and irregular cell growth, ultimately 
leading to cancer development[2,5,6]. 
The mutation in the CDH1 gene can occur spo-
radically or can be inherited through an autosomal 
dominant inheritance pattern. The CDH1 gene is a tumor 
suppressor gene and thereby requires a second hit, 
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a somatic mutation in the second E-cadherin allele, 
in order to cause cancer progression. In individuals 
with germline mutations of CDH1, the second hit has 
been shown to occur mostly through CDH1 promoter 
hypermethylation, with fewer instances of loss of 
heterozygosity[9,10]. One study found that no additional 
somatic mutations beyond promoter hypermethylation 
in those with germline CDH1 mutations were required 
for cancer formation[9].
Because HDGC originates as discrete foci in the 
gastric submucosa, it produces no grossly visible 
architectural changes[2,6]. The presence of cancer as a 
result is hidden in its early stages on endoscopy and 
nearly impossible to detect with sampling by random 
biopsies[2,6]. Currently there is a lack of evidence regard-
ing the timing of metastatic signet ring gastric carcinoma, 
though evidence suggests that there may be a dormant 
period before metastasis[11,12]. The progression of diffuse 
gastric cancer seems to be particularly aggressive in 
young individuals, as only 10% of those under age 40 
who develop symptomatic and invasive diffuse gastric 
cancer have curable disease[12,13]. Thus the IGCLC 
recommends that individuals with the CDH1 gene 
mutation, even without evidence of gastric cancer, 
undergo prophylactic total gastrectomy between ages 
20 to 30 years, rather than surveillance endoscopy[2] 
(Table 1). If a person is unwilling to undergo prophy-
lactic gastrectomy, the IGCLC recommends intensive 
endoscopic surveillance at an expert center[2]. Other 
means of early cancer detection have also been met 
with limited success; PET imaging has a high rate of 
false negatives in mucinous cancers, such as occurs in 
HDGC[14]. 
Given the low yield of random biopies and the 
negative PET scan, our patient was highly fortunate 
that the random biopsy taken in the distal gastric body 
revealed the presence of cancer. This is especially lucky 





































Figure 1  Family pedigree. Shading indicates presence of diagnosed HDGC. Strike through represents negative testing for the CDH1 gene mutation. Red square 
represents our patient.
Figure 2  Histology of the gastric lamina propria showing signet ring cells. A: HE stain (× 200); B: Cytokeratin AE1.3 antibody staining showing the presence 
of keratin (× 200); C: Mucicarmine stain showing the presence of mucin (× 200).
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on endoscopy and the normal biopsies taken in the 
other gastric locations. At the time of gastrectomy, our 
patient’s cancer was staged a T1. Thus, our patient’s 
cancer was effectively caught early, before it metasta-
sized. Furthermore, the 70%-80% penetrance[2] of 
the CDH1 mutation coupled with the patient’s diagnosis 
of gastric cancer 10 years prior and the death of 3 
family members due to metastatic gastric carcinoma, 
suggest that the patient’s cancer would have ultimately 
progressed if it had been left undetected. 
Due to the difficulty in early detection, the high 
penetrance of the CDH1 gene, and the early onset of 
incurable disease, genetic testing is the only beneficial 
means of detecting and preventing HDGC in individuals 
with a family history. The IGCLC therefore recommends 
CDH1 genetic testing in all individuals who meet one of 
the following criteria: 2 or more cases of gastric cancer 
in a family with 1 confirmed diffuse type in 1st or 2nd 
degree relatives independent of age, presence of diffuse 
gastric cancer in an individual less than age 50, and 
personal or family history of diffuse gastric cancer and 
lobular breast cancer with one of the diagnoses before 
age 50[2].  Genetic testing may also be considered in 
individuals with bilateral lobular breast cancer under 
the age of 50 or in families with multiple members 
with lobular breast cancer (with two of these relatives 
younger than 50 years)[2]. As the CDH1 gene mutation 
has also been linked to cleft lip and palate, the IGCLC 
suggests that genetic testing may be considered in 
families with a history of cleft lip/palate and diffuse 
gastric cancer[2].
Given the risk of lobular breast cancer, the IGCLC 
recommends breast screening from age 30 (composed 
of annual clinical breast exams and bilateral MRIs)[2]. The 
IGCLC does not recommend prophylactic mastectomy 
in individuals with the CDH1 mutation, though suggests 
that mastectomy can be considered on a case by case 
basis[2]. Colon cancer screening is recommended only in 
families with HDGC related colon cancer starting at age 
40 or 10 years younger than the affected individual[2].
At the time of initial diagnosis of gastric cancer, our 
patient had 3 first-degree relatives who had already 
succumbed to metastatic disease. However, these 3 
relatives died prior to the discovery of the CDH1 gene 
mutation in 1998[15] and were thus unable to undergo 
genetic testing. While our patient was initially diagnosed 
with gastric cancer in 2003, the expense of genetic 
testing and the lack of availability of genetic testing in 
office based medical practices precluded our patient 
from undergoing gene analysis. By the time of our 
patient’s cancer recurrence in 2012, the widespread 
availability of genetic testing allowed our patient to 
undergo screening and also encourage screening in his 
family members. By doing so, the patient prompted 
life saving measures in his family: the CDH1 gene 
mutation was detected in 12 relatives and evidence of 
histological gastric cancer was detected in 8 relatives 
who underwent prophylactic gastrectomy. This case 
highlights the importance of gathering a thorough family 
history, especially as it relates to gastric cancer, and 
encouraging genetic testing in patients who meet the 
IGCLC criteria. This case also emphasizes the benefit of 
affordable and available genetic testing and the need to 
make genetic testing available for office based practices. 
ARTICLE HIGHLIGHTS
Case characteristics
A 58-year-old male with a past medical history of gastric signet ring 
adenocarcinoma, treated with partial gastrectomy, presenting to our practice 
for triennial esophagogastroduodenoscopies (EGD) for surveillance of cancer 
recurrence. Patient’s family history was significant for 3 first degree relatives 
with gastric cancer. EGD performed showed normal appearing mucosa, though 
biopsy from the distal gastric body revealed adenocarcinoma with signet cells.
Clinical diagnosis
Patient was asymptomatic at diagnosis.
Differential diagnosis
The differential diagnosis included spontaneous gastric cancer reoccurrence or 
a hereditary gastric cancer syndrome.
Table 1  CDH1 related cancer risks and International Gastric Cancer Linkage Consortium 8th workshop management recommendations
Gastric cancer Lobular breast cancer Colon cancer
Lifetime cancer risk 80% 60% Unknown
Surveillance EGD surveillance in persons not willing to 
undergo prophylactic gastrectomy
Annual clinical breast exams Colon cancer screening in HDGC families 
with colon cancer from age 0 or 0 yr 
younger than the youngest diagnosis of 
colon cancer
If CDH1 + with no evidence of cancer, EGD 
surveillance, usually starting at age 6 until 
time of prophylactic gastrectomy per IGCLC 7 
guideline[]
Bilateral breast MRI starting at age 30 Repeat colonoscopy at 3-5 yr intervals per 
IGCLC 7 guidelines[]
Therapy Suggest prophylactic gastrectomy between age 
20-30 if CDH1 + without evidence of cancer
Suggests gastrectomy if evidence of cancer 
regardless of age
Prophylactic mastectomy not 
recommended, but may be considered on 
case by case basis
Not available
EGD: Esophagogastroduodenoscopies; HDGC: Hereditary diffuse gastric cancer; IGCLC: International Gastric Cancer Linkage Consortium.
 ARTICLE HIGHLIGHTS
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Laboratory diagnosis
The patient underwent a gene panel for known mutations linked to gas-
trointestinal cancers. The patient tested positive for a mutation in the CDH1 
gene which confirmed the presence of hereditary diffuse gastric cancer.
Imaging diagnosis
Endoscopic ultrasound revealed no submucosal or mucosal aberrations. PET/
CT imaging revealed no abnormalities suggestive of metastatic disease.  
Pathological diagnosis
Examination of the pathologic specimen after total gastrectomy, confirmed a 
0.6-cm poorly differentiated signet ring cell carcinoma in the lesser curvature of 
the stomach with invasion into the lamina propria. 
Treatment
The patient underwent total gastrectomy. The patient encouraged genetic 
testing in his 21 family members, of which 12 were found to have the CDH1 
gene mutation.
Related reports
There are currently other case reports of families with the CDH1 gene mutation, 
though none with as extensive a family pedigree.
Term explanation
HDGC is an inherited form of gastric cancer, with majority caused by an 
autosomal dominant genetic mutation in the CDH1 gene.
Experiences and lessons
This case highlights the importance of gathering a thorough family history, 
especially as it relates to gastric cancer, and encouraging genetic testing in 
patients who meet the International Gastric Cancer Linkage Consortium criteria.
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